87726 Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 

Form Number: 8725. 

Abstract: Treasury Decision (TD) 8379 

provide rules relating to the manner and 

method of reporting and paying the 

nondeductible 50 percent excise tax 

imposed by section 5881 of the Internal 

Revenue Code with respect to the 

receipt of greenmail. The reporting 

requirements will be used to verify that 

the excise tax imposed under section 

5881 is properly reported and timely 

paid. Form 8725 is used by persons who 

receive ‘‘greenmail’’ to compute and pay 

the excise tax on greenmail imposed 

under Internal Revenue Code section 

5881. IRS uses the information to verify 

that the correct amount of tax has been 

reported. 

Current Actions: There is no change to 

these existing collection requirements. 

Type of Review: Extension of a 

currently approved collection. 

Affected Public: Individuals and 

business or other for-profit 

organizations. 

Estimated Number of Responses: 12. 

Estimated Time per Response: 7 

hours, 37 minutes. 

Estimated Total Annual Burden 

Hours: 92. 

The following paragraph applies to all 

of the collections of information covered 

by this notice: 

An agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless the collection of information 

displays a valid OMB control number. 

Books or records relating to a collection 

of information must be retained as long 

as their contents may become material 

in the administration of any internal 

revenue law. Generally, tax returns and 

tax return information are confidential, 

as required by 26 U.S.C. 6103. 

Request for Comments: Comments 

submitted in response to this notice will 

be summarized and/or included in the 

request for OMB approval. Comments 

will be of public record. Comments are 

invited on: (a) whether the collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information has practical utility; (b) the 

accuracy of the agency’s estimate of the 

burden of the collection of information; 

(c) ways to enhance the quality, utility, 

and clarity of the information to be 

collected; (d) ways to minimize the 

burden of the collection of information 

on or other forms of information 

technology; and (e) estimates of capital 

or start-up costs and costs of operation, 

maintenance, and purchase of services 

to provide information. 

Approved: October 30, 2024. 

Molly J. Stasko, 

Senior Tax Analyst. 

[FR Doc. 2024–25606 Filed 11–1–24; 8:45 am] 

BILLING CODE 4830–01–P 

U.S.-CHINA ECONOMIC AND 

SECURITY REVIEW COMMISSION 

Notice of Open Public Event 

AGENCY: U.S.-China Economic and 

Security Review Commission. 

ACTION: Notice of open public event. 

SUMMARY: Notice is hereby given of the 

following open public event of the U.S.- 

China Economic and Security Review 

Commission. The Commission is 

mandated by Congress to monitor, 

investigate, and report to Congress 

annually on ‘‘the national security 

implications of the bilateral trade and 

economic relationship between the 

United States and the People’s Republic 

of China.’’ Pursuant to this mandate, the 

Commission will hold a public release 

of its 2024 Annual Report to Congress 

in Washington, DC on November 19, 

2024. 

DATES: The release is scheduled for 

Tuesday, November 19, 2024 at 10:30 

a.m. 

ADDRESSES: This release will be held inperson at or near the U.S. Capitol and 

adjacent Congressional office buildings 

(specific building and room number to 

be announced) and online via live 

webcast on the Commission’s website at 

www.uscc.gov. Please check the 

Commission’s website for an 

announcement on the specific event 

location once determined. Instructions 

on how to view the webcast and submit 

questions or participate in the question 

and answer session will also be posted 

at USCC.gov. Reservations are not 

required to attend. 

FOR FURTHER INFORMATION CONTACT: Any 

member of the public seeking further 

information concerning the event 

should contact Jameson Cunningham, 

444 North Capitol Street NW, Suite 602, 

Washington, DC 20001; telephone: 202– 

624–1496, or via email at jcunningham@

uscc.gov. Reservations are not required 

to attend. 

ADA Accessibility: For questions 

about the accessibility of the event or to 

request an accommodation, please 

contact Jameson Cunningham at 202– 

624–1496, or via email at jcunningham@

uscc.gov. Requests for an 

accommodation should be made as soon 

as possible, and at least five business 

days prior to the event. 

SUPPLEMENTARY INFORMATION: 

Topics to Be Discussed: The 

Commission’s 2024 Annual Report to 

Congress addresses key findings and 

recommendations for Congressional 

action based upon the Commission’s 

hearings, research, and review of the 

areas designated by Congress in its 

mandate, including focused work this 

year on: a review of economics, trade, 

security, and foreign affairs 

developments in China and in the U.S.- 

China relationship in 2024; China’s 

progress in emerging technologies at the 

forefront of U.S.-China competition; the 

risks to consumer product safety posed 

by Chinese imports; China’s counterintervention capabilities in the IndoPacific region; U.S. strategies to address 

China’s nonmarket practices and other 

aspects of intersecting economic and 

national security challenges associated 

with China; the Chinese Communist 

Party’s efforts to prepare Chinese society 

for a crisis or conflict; and changing 

relations between China and the Middle 

East, Taiwan, and Hong Kong. 

Authority: Congress created the U.S.- 

China Economic and Security Review 

Commission in 2000 in the National 

Defense Authorization Act (Pub. L. 106– 

398), as amended by division P of the 

Consolidated Appropriations 

Resolution, 2003 (Pub. L. 108–7), as 

amended by Pub. L. 109–108 (November 

22, 2005), as amended by Pub. L. 113– 

291 (December 19, 2014). 

Dated: October 28, 2024. 

Christopher P. Fioravante, 

Deputy Executive Director, U.S.-China 

Economic and Security Review Commission. 

[FR Doc. 2024–25579 Filed 11–1–24; 8:45 am] 

BILLING CODE 1137–00–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Joint Biomedical Laboratory Research 

and Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board, Notice 

of Meeting 

The Department of Veterans Affairs 

(VA) gives notice under the Federal 

Advisory Committee Act, 5 U.S.C. 

ch.10, that a meeting of the Joint 

Biomedical Laboratory Research and 

Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board will be 

held January 7, 2025, via WebEx. The 

meeting will be held between 3 and 5 

p.m. EDT. The meeting will be closed to 

the public from 3:30–5 p.m. EDT for 

scientific review and the discussion, 

examination, and reference to the 

research applications. Discussions will 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 87727 

involve reference to staff and consultant 

critiques of research proposals. 

Discussions will deal with scientific 

merit of each proposal and 

qualifications of personnel conducting 

the studies, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Additionally, premature disclosure of 

research information could significantly 

obstruct implementation of proposed 

agency action regarding the research 

proposals. As provided by Public Law 

92–463 subsection 10(d), and as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with Title 5 U.S.C. 552b(c) (6) and 

(9)(B). 

The objective of the Board is to 

provide for the fair and equitable 

selection of the most meritorious 

research projects for support by VA 

research funds and to offer advice for 

research program officials on program 

priorities and policies. The ultimate 

objective of the Board is to ensure the 

high quality and mission relevance of 

VA’s legislatively mandated Biomedical 

Laboratory and Clinical Science 

Research and Development programs. 

Board members advise the Directors 

of the Biomedical Laboratory and 

Clinical Sciences Research Services and 

the Chief Research and Development 

Officer on the scientific and technical 

merit, mission relevance, and protection 

of human subjects of Biomedical 

Laboratory and Clinical Sciences 

Research and Development proposals. 

The Board does not consider grants, 

contracts, or other forms of extramural 

research. 

Members of the public may attend the 

open portion of the meeting. The time 

limited agenda does not enable public 

comments or presentations. To attend 

the open portion of the meeting (3–3:30 

p.m. EDT), the public may join by 

dialing the phone number 1–404–397– 

1596 and entering the meeting number 

(access code): 2823 274 3705. Public 

comments accepted during the open 

portion of the meeting and public 

stakeholders who want to speak to the 

committee will be afforded three 

minutes during the public comment 

period. These stakeholders must notify 

the DFO of their intention to speak to 

the committee. 

Written public comments must be 

sent to Michael R. Burgio, Ph.D., 

Designated Federal Officer, Advisory 

Committee Management Office, 811 

Vermont Avenue NW, Room 4342A, 

Washington, DC 20006, or to 

Michael.Burgio@va.gov, at least five 

days before the meeting. The written 

public comments will be shared with 

the Board members. The public may not 

attend the closed portion of the meeting 

as disclosure of research information 

could significantly obstruct 

implementation of proposed agency 

action regarding the research proposals 

(per Pub. L. 92–463 subsection 10(d), as 

amended by Pub. L. 94–409, closing the 

committee meeting is in accordance 

with 5 U.S.C. 552b(c) (6) and (9)(B)). 

Dated: October 29, 2024. 

LaTonya L. Small, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2024–25538 Filed 11–1–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Joint Biomedical Laboratory Research 

and Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board, 

AMENDED, Notice of Meeting 

The Department of Veterans Affairs 

(VA) gives notice under the Federal 

Advisory Committee Act, 5 U.S.C. 

ch.10, that a meeting of the Joint 

Biomedical Laboratory Research and 

Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board will be 

held January 7, 2025, via WebEx. The 

meeting will be held between 3 and 5 

p.m. EDT. The meeting will be closed to 

the public from 3:30–5 p.m. EDT for 

scientific review and the discussion, 

examination, and reference to the 

research applications. Discussions will 

involve reference to staff and consultant 

critiques of research proposals. 

Discussions will deal with scientific 

merit of each proposal and 

qualifications of personnel conducting 

the studies, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Additionally, premature disclosure of 

research information could significantly 

obstruct implementation of proposed 

agency action regarding the research 

proposals. As provided by Public Law 

92–463 subsection 10(d), and as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with 5 U.S.C. 552b(c)(6) and (9)(B). 

The objective of the Board is to 

provide for the fair and equitable 

selection of the most meritorious 

research projects for support by VA 

research funds and to offer advice for 

research program officials on program 

priorities and policies. The ultimate 

objective of the Board is to ensure the 

high quality and mission relevance of 

VA’s legislatively mandated Biomedical 

Laboratory and Clinical Science 

Research and Development programs. 

Board members advise the Directors 

of the Biomedical Laboratory and 

Clinical Sciences Research Services and 

the Chief Research and Development 

Officer on the scientific and technical 

merit, mission relevance, and protection 

of human subjects of Biomedical 

Laboratory and Clinical Sciences 

Research and Development proposals. 

The Board does not consider grants, 

contracts, or other forms of extramural 

research. 

Members of the public may attend the 

open portion of the meeting. The time 

limited agenda does not enable public 

comments or presentations. To attend 

the open portion of the meeting (3–3:30 

p.m. EDT), the public may join by 

dialing the phone number 1–404–397– 

1596 and entering the meeting number 

(access code): 2823 274 3705. These 

stakeholders must notify the DFO of 

their intention to speak to the 

committee. 

Written public comments must be 

sent to Michael R. Burgio, Ph.D., 

Designated Federal Officer, Advisory 

Committee Management Office, 811 

Vermont Avenue NW, Room 4342A, 

Washington, DC 20006, or to 

Michael.Burgio@va.gov, at least five 

days before the meeting. The written 

public comments will be shared with 

the Board members. The public may not 

attend the closed portion of the meeting 

as disclosure of research information 

could significantly obstruct 

implementation of proposed agency 

action regarding the research proposals 

(per Pub. L. 92–463 subsection 10(d), as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with 5 U.S.C. 552b(c)(6) and (9)(B). 

Dated: October 29, 2024. 

LaTonya L. Small, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2024–25550 Filed 11–1–24; 8:45 am] 

BILLING CODE 8320–01–P 


lotter on DSK11XQN23PROD with NOTICES1